Bayer’s Stivarga® (regorafenib) received US FDA approval to treat patients with hepatocellular carcinoma (HCC), the most common form of liver …

You have read of your 8 free articles this month.

Subscribe to
Medgenera All-Access

Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.

Access articles & resources worth up to US $4, 000 per month.

Authentic, Ad-free Reporting
High-quality, Exclusive Content
Original Market Research Reports
Original Resources & Databases
Global Surveys & Guidelines
Lowest Subscription Pricing

Healthcare News You Won't Read Elsewhere

Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.

Access articles & resources worth up to $4000.

More in New Drug Approvals

New Drug Approvals

8 Facts about the Second FDA-Approved Gene Therapy for Cancer

Cancer is a gloomy word. When a person comes to know about his cancer for the first time, all his ...

New Drug Approvals

Breakthrough Lens Technology Helps Cataract Patients Go Glass Free

With increasing age, many people face various eye-related disorders. One of the most common conditions among them is the cataract. ...

New Drug Approvals

FDA Approves First Two-Drug Therapy for HIV Treatment

The US FDA approved GlaxoSmithKline’s (GSK) Juluca® as the first complete regimen containing only two drugs for the treatment of ...

New Drug Approvals

First Three-in-One Inhaler Therapy for Lung Disease, COPD Reaches Europe

UPDATE:  GlaxoSmithKline/Innoviva‘s single inhaler, three-in-one therapy- Trelegy Ellipta received marketing approval in the European Union for the treatment of adult patients ...

Most Popular


7 New Ideas to Start a Healthcare Business in India (2018)

Seven new #healthcare #business ideas in India in 2018. Which one would you prefer to pursue?


Pharma Patents: Can India Reward Incremental Innovation?

Chandramouli Natarajan is an Associate Scientist, Ricon pharma LLC, Denville, USA. He has presented his opinion and views on the Pharmaceutical patents issues in India. This article is available for free to read and share.

Leave a reply